Retapamulin: An antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus

Journal of Drugs in Dermatology

Volumn 9, Issue 10, 2010, Pages 1198-1204

  Weinberg, Jeffrey M ^a   Tyring, Stephen K ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; ERYTHROMYCIN; FUSIDATE SODIUM; LINEZOLID; METICILLIN; OXACILLIN; PENICILLIN BINDING PROTEIN 2A; PENICILLIN G; PLACEBO; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETAPAMULIN; VANCOMYCIN; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; APPLICATION SITE IRRITATION; ARTICLE; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERIUM ISOLATION; CHILDHOOD DISEASE; COMPARATIVE EFFECTIVENESS; DERMATITIS; DNA REPLICATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; ENTEROCOCCUS FAECALIS; HOSPITAL INFECTION; HUMAN; IMPETIGO; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY (TOPIC); MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PENICILLIN RESISTANCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARILY INFECTED DERMATITIS; SECONDARILY INFECTED TRAUMATIC LESION; SKIN INJURY; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; TREATMENT RESPONSE; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION; DRUG EFFECT;

ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; MUPIROCIN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANCE;

EID: 78049503513     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Boyle-Vavra S, Daum RS. Community-acquired methicillin-resistant Staphylococcus aureus: The role of Panton-Valentine leukocidin. Lab Invest. 2007;87(1):3-9. (Pubitemid 44973648)
2. Nizet V. Understanding how leading bacterial pathogens subvert innate immunity to reveal novel therapeutic targets. J Allergy Clin Immunol. 2007;120(1):13-22. (Pubitemid 46990514)
3. Lowy FD. Staphylococcus aureus infections. N Engl J Med. 1998;339(8):520-532.
4. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: Cohort study. BMJ. 2006;333(7562):281.
5. McCaig LF, McDonald LC, Mandal S, Jernigan DB. Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care. Emerg Infect Dis. 2006;12(11):1715-1723. (Pubitemid 44674248)
6. Cole C, Gazewood J. Diagnosis and treatment of impetigo. Am Fam Physician. 2007;75(6):859-864.
7. Hedrick J. Acute bacterial skin infections in pediatric medicine: Current issues in presentation and treatment. Paediatr Drugs. 2003;5(Suppl 1):35-46. (Pubitemid 37082991)
8. Spellberg B. Antibiotic resistance and antibiotic development. Lancet Infect Dis. 2008;8(4):211-212. (Pubitemid 351382021)
9. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(26):565-567.
10. Lowy FD. Antimicrobial resistance: The example of Staphylococcus aureus. J Clin Invest. 2003;111(9):1265-1273. (Pubitemid 36554694)
11. Niederman MS. Principles of appropriate antibiotic use. Int J Antimicrob Agents. 2005;26(Suppl 3):S170-S175.
12. Leclercq R. Safeguarding future antimicrobial options: Strategies to minimize resistance. Clin Microbiol Infect. 2001;7(Suppl 3):18-23.
13. Kumana CR, Ching TY, Kong Y, et al. Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant Staphylococcus aureus infections. Br J Clin Pharmacol. 2001;52(4):427-432. (Pubitemid 32939445)
14. Rittenhouse S, Biswas S, Broskey J, et al. Selection of retapamulin, a novel pleuromutilin for topical use. Antimicrob Agents Chemother. 2006;50(11):3882-3885. (Pubitemid 44684907)
15. Champney WS, Rodgers WK. Retapamulin inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007;51(9):3385-3387. (Pubitemid 350067559)
16. Yan K, Madden L, Choudhry AE, et al. Biochemical characterization of the interactions of the novel pleuromutilin derivative retapamulin with bacterial ribosomes. Antimicrob Agents Chemother. 2006;50(11):3875-3881. (Pubitemid 44684906)
17. Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Microbiological profile of a new topical antibacterial: Retapamulin ointment 1%. Expert Rev Anti Infect Ther. 2009;7(3):269-279.
18. Kosowska-Shick K, Clark C, Credito K, et al. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother. 2006;50(2):765- 769.
19. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med. 1999;340(7):556-557. (Pubitemid 29093292)
20. Barber M. Methicillin-resistant staphylococci. J Clin Pathol. 1961;14:385-393.
21. Cosgrove SE, Sakoulas G, Perencevich EN, et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis. 2003;36(1):53-59. (Pubitemid 36099097)
22. Simor AE, Stuart TL, Louie L, et al. Mupirocin-resistant, methicillinresistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother. 2007;51(11):3880-3886. (Pubitemid 350057784)
23. Tillotson GS, Draghi DC, Sahm DF, et al. Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-2007: Laboratory-based surveillance study. J Antimicrob Chemother. 2008;62(1):109-115. (Pubitemid 351865881)
24. Sterile Vancomycin Hydrocloride [package insert]. Liberty Corner, NJ: GeneraMedix. 2007.
25. ZYVOX® [package insert]. New York, NY: Pfizer, Inc. 2004.
26. CUBICIN® [package insert]. Lexington, MA: Cubist Pharmaceuticals, Inc. 2008.
27. Ubukata K, Itoh-Yamashita N, Konno M. Cloning and expression of the norA gene for fluoroquinolone resistance in Staphylococcus aureus. Antimicrob Agents Chemother. 1989;33(9):1535-1539. (Pubitemid 19228009)
28. Chambers HF. Methicillin resistance in staphylococci: Molecular and biochemical basis and clinical implications. Clin Microbiol Rev. 1997;10(4):781-791. (Pubitemid 27477734)
29. Ng EY, Trucksis M, Hooper DC. Quinolone resistance mediated by norA: Physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome. Antimicrob Agents Chemother. 1994;38(6):1345-1355. (Pubitemid 24170718)
30. Upton A, Lang S, Heffernan H. Mupirocin and Staphylococcus aureus: A recent paradigm of emerging antibiotic resistance. J Antimicrob Chemother. 2003;51(3):613-617. (Pubitemid 36336154)
31. Moy JA, Caldwell-Brown D, Lin AN, Pappa KA, Carter DM. Mupirocin- resistant Staphylococcus aureus after long-term treatment of patients with epidermolysis bullosa. J Am Acad Dermatol. 1990;22(5 Pt 1):893-895. (Pubitemid 20154111)
32. Farmer TH, Gilbart J, Elson SW. Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus. J Antimicrob Chemother. 1992;30(5):587-596. (Pubitemid 23009005)
33. Gilbart J, Perry CR, Slocombe B. High-level mupirocin resistance in Staphylococcus aureus: Evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother. 1993;37(1):32-38. (Pubitemid 23019165)
34. Deshpande LM, Fix AM, Pfaller MA, Jones RN. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY Antimicrobial Surveillance Program (2000): Correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis. 2002;42(4):283-290. (Pubitemid 34455021)
35. Netto dos Santos KR, De Souza Fonseca L, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol. 1996;17(12):813-816. (Pubitemid 126478536)
36. Raju V MK, Mankin P, Gray B. Surveillance for mupirocin resistance among MRSA clinical isolates. Paper presented at: 2008 Conference on Antimicrobial Resistance; June 23-25, 2008; Bethesda, MD.
37. Lio PA, Kaye ET. Topical antibacterial agents. Infect Dis Clin North Am. 2004;18(3):717-733. (Pubitemid 39078734)
38. Kirst HA, Thompson DG, Nicas TI. Historical yearly usage of vancomycin. Antimicrob Agents Chemother. 1998;42(5):1303-1304.
39. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40(1):135-136. (Pubitemid 27341646)
40. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N Engl J Med. 1999;340(7):493-501.
41. Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand. 2002;81(5):443-450. (Pubitemid 34527151)
42. Gonzalez-Zorn B, Courvalin P. VanA-mediated high level glycopeptide resistance in MRSA. Lancet Infect Dis. 2003;3(2):67-68. (Pubitemid 36164198)
43. Sievert DM, Rudrik JT, Patel JB, et al. Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006. Clin Infect Dis. 2008;46(5):668-674. (Pubitemid 351321548)
44. ALTABAX [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
45. Yang LP, Keam SJ. Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs. 2008;68(6):855-873. (Pubitemid 351550533)
46. Woodford N, Afzal-Shah M, Warner M, Livermore DM. In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin. J Antimicrob Chemother. 2008;62(4):766-768.
47. Jones RN, Fritsche TR, Sader HS, Ross JE. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant grampositive cocci. Antimicrob Agents Chemother. 2006;50(7):2583- 2586.
48. Mendes RE, Deshpande LM, Castanheira M, et al. First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States. Antimicrob Agents Chemother. 2008;52(6):2244-2246. (Pubitemid 351758569)
49. Gentry DR, McCloskey L, Gwynn MN, et al. Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus. Antimicrob Agents Chemother. 2008;52(12):4507-4509.
50. Gentry DR, Rittenhouse SF, McCloskey L, Holmes DJ. Stepwise exposure of Staphylococcus aureus to pleuromutilins is associated with stepwise acquisition of mutations in rplC and minimally affects susceptibility to retapamulin. Antimicrob Agents Chemother. 2007;51(6):2048-2052. (Pubitemid 46903093)
51. Koning S, Van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: Randomized double-blind multicentre placebo-controlled trial. Br J Dermatol. 2008;158(5):1077-1082. (Pubitemid 351521449)
52. Oranje AP, Chosidow O, Sacchidanand S, et al. Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: A randomized, observer-blinded, noninferiority study. Dermatology. 2007;215(4):331-340. (Pubitemid 47519263)
53. Free A, Roth E, Dalessandro M, et al. Retapamulin ointment twice daily for 5 days vs oral cephalexin twice daily for 10 days for empiric treatment of secondarily infected traumatic lesions of the skin. SKINmed. 2006;5(5):224-232.
54. Parish LC, Jorizzo JL, Breton JJ, et al. Topical retapamulin ointment (1%, wt/wt) twice daily for 5 days versus oral cephalexin twice daily for 10 days in the treatment of secondarily infected dermatitis: Results of a randomized controlled trial. J Am Acad Dermatol. 2006;55(6):1003-1013. (Pubitemid 44716499)
55. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296- 1310. (Pubitemid 32804122)